Rhythm Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Rhythm Pharmaceuticals, Inc.

Apr-09	Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 RYTM GlobeNewswire
Apr-03	Rhythm Pharmaceuticals Announces Changes to Board of Directors RYTM GlobeNewswire
Mar-26	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment RYTM GlobeNewswire
Mar-19	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity RYTM +5.18% GlobeNewswire
Mar-16	Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial RYTM GlobeNewswire
Mar-01	Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity RYTM GlobeNewswire
Feb-26	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update RYTM GlobeNewswire
Feb-17	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 RYTM GlobeNewswire
Feb-05	Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit RYTM GlobeNewswire
Jan-09	Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones RYTM GlobeNewswire
Dec-11	Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome RYTM +12.26% GlobeNewswire
Dec-10	Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome RYTM GlobeNewswire
Nov-10	Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek 2025 RYTM GlobeNewswire
Nov-07	Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity RYTM GlobeNewswire
Nov-05	Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program RYTM -5.26% GlobeNewswire
Nov-04	Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update RYTM -7.69% GlobeNewswire
Oct-21	Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 RYTM GlobeNewswire
Aug-27	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences RYTM GlobeNewswire
Aug-20	Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity RYTM GlobeNewswire
Aug-05	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update RYTM GlobeNewswire
Jul-22	Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 RYTM GlobeNewswire
Jul-12	Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 RYTM GlobeNewswire
Jul-10	Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock RYTM GlobeNewswire
Jul-09	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock RYTM +36.63% GlobeNewswire
Jul-09	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity RYTM +36.63% GlobeNewswire
Jul-08	Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity RYTM GlobeNewswire
Jun-25	Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 RYTM GlobeNewswire
May-14	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program RYTM GlobeNewswire
May-07	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update RYTM GlobeNewswire
May-06	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences RYTM GlobeNewswire

Rhythm Pharmaceuticals, Inc.

Recent Articles by Rhythm Pharmaceuticals, Inc.

Upgrade your Finviz experience